Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer
Conditions: Bladder Adenocarcinoma; Bladder Mixed Adenocarcinoma; Bladder Squamous Cell Carcinoma; Bladder Urothelial Carcinoma; Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant; Infiltrating Bladder Urothelial Carcinoma With Giant Cells; Infiltrating Bladder Urothelia l Carcinoma With Glandular Differentiation; Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation; Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant; Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant; Infiltrating Bladder Urothelial Carc inoma, Nested Variant; Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant Interventions: Drug: Carboplatin; Drug: Cisplatin; Procedure: Cystectomy; Drug: Doxorubicin; Biological: Durvalumab; Drug: Gemcitabine; Drug: Methotrexate; Drug: Vinblastine Sponsors: Stanford University; AstraZeneca Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | AstraZeneca | Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Methotrexate | Micropapillary Carcinoma | Research